According to the business intelligence report titled ‘GLOBAL Injectable Drug Delivery Market 2019-2028’, available with Market Study Report, global injectable drug delivery market is projected to record a compound annual growth rate of 8.66% over 2019-2028.
 

Rise in geriatric population, growing incidences of autoimmune diseases, and advancements in technology are key factors proliferating global injectable drug delivery market growth. Additionally, high expenditure on healthcare, and availability of advanced injectable systems will also facilitate the industry outlook.  
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3552936/
 

On the other hand, strict government regulations for usage of drug delivery systems, availability of alternatives, and high costs of production are hampering the growth of global injectable drug delivery industry.
 

Based on device type, worldwide injectable drug delivery market is divided into pen injector, needle-free injector (spring-based, gas-based), auto injector, and prefilled syringe (glass, plastic).
 

Speaking of route of administration, the industry is bifurcated into intravenous, intramuscular, subcutaneous, and others. Moving on to end user terrain, the marketplace is classified into ambulatory care, hospitals, home-based, clinics/physician offices, and others..
 

From the regional frame of reference, Asia Pacific injectable drug delivery market is speculated to showcase lucrative growth trends over the forecast period. An improvement in life expectancy as a result of scientific advancements is responsible to rise in geriatric population. According to trusted reports, 15.02% of Chinese population was aged 60 years and above in 2015. This percentage is speculated to reach 25.3% by 2030. Large geriatric population base who are more likely to suffer from chronic pain, diabetes, CVD, and autoimmune diseases among others will foster the product demand.
 

Key players influencing global injectable drug delivery industry trends are Becton Dickinson & Company (BD), Gerresheimer AG, Elcam Medical ACS. Ltd., Eli Lilly & Company, Pfizer Inc., West Pharmaceutical Services Inc., Schott AG, Terumo Corporation, Novo Nordisk A/S, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Novartis International AG, Baxter International Inc., Ypsomed AG, and INJEX Pharma AG.